What compounds target SIK3?

BiohacksAI has identified 26 compounds that interact with SIK3 (SIK family kinase 3). Top compounds include: sb 203580, vandetanib, ruxolitinib, bosutinib, midostaurin. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is SIK3 (SIK family kinase)?

SIK3 is SIK family kinase 3. It is a molecular target for 26 compounds documented in PubMed bioassay data. UniProt ID: Q9Y2K2. NCBI Gene ID: 23387.

SIK3

MOLECULAR TARGET

SIK family kinase 3

UniProt: Q9Y2K2 NCBI Gene: 2338726 compounds

SIK3 (SIK family kinase 3) is targeted by 26 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting SIK3

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	sb 203580	4.92	136
2	vandetanib	4.30	73
3	ruxolitinib	4.23	68
4	bosutinib	4.08	58
5	midostaurin	3.85	46
6	canertinib	3.53	33
7	tae 684	3.43	30
8	fedratinib	3.40	29
9	saracatinib	3.33	27
10	dabrafenib	3.30	26
11	at 9283	3.09	21
12	lestaurtinib	3.04	20
13	momelotinib	2.89	17
14	k 252a	2.83	16
15	milciclib	2.77	15
16	crenolanib	2.71	14
17	kw 2449	2.64	13
18	zotiraciclib	2.56	12
19	azd 7762	2.30	9
20	y 39983	2.20	8
21	cyc 116	2.08	7
22	tanzisertib	1.95	6
23	pf 03814735	1.79	5
24	ucn 01	1.79	5
25	osi 632	1.79	5
26	Dasatinib	0.69	1

About SIK3 as a Drug Target

SIK3 (SIK family kinase 3) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 26 compounds with documented SIK3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

SIK3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.